These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18381947)

  • 21. A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
    Doi T; Takahashi S; Aoki D; Yonemori K; Hara H; Hasegawa K; Takehara K; Harano K; Yunokawa M; Nomura H; Shimoi T; Horie K; Ogasawara A; Okame S
    Cancer Chemother Pharmacol; 2024 Jun; 93(6):605-616. PubMed ID: 38411735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
    Infante JR; Ramanathan RK; George D; Tan E; Quinlan M; Liu A; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):729-37. PubMed ID: 25648347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
    Banerji U; Camidge DR; Verheul HM; Agarwal R; Sarker D; Kaye SB; Desar IM; Timmer-Bonte JN; Eckhardt SG; Lewis KD; Brown KH; Cantarini MV; Morris C; George SM; Smith PD; van Herpen CM
    Clin Cancer Res; 2010 Mar; 16(5):1613-23. PubMed ID: 20179232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
    Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
    Tabernero J; Bahleda R; Dienstmann R; Infante JR; Mita A; Italiano A; Calvo E; Moreno V; Adamo B; Gazzah A; Zhong B; Platero SJ; Smit JW; Stuyckens K; Chatterjee-Kishore M; Rodon J; Peddareddigari V; Luo FR; Soria JC
    J Clin Oncol; 2015 Oct; 33(30):3401-8. PubMed ID: 26324363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
    Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
    Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
    Yap TA; Arkenau HT; Camidge DR; George S; Serkova NJ; Gwyther SJ; Spratlin JL; Lal R; Spicer J; Desouza NM; Leach MO; Chick J; Poondru S; Boinpally R; Gedrich R; Brock K; Stephens A; Eckhardt SG; Kaye SB; Demetri G; Scurr M
    Clin Cancer Res; 2013 Feb; 19(4):909-19. PubMed ID: 23403628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors.
    van der Biessen DA; Burger H; de Bruijn P; Lamers CH; Naus N; Loferer H; Wiemer EA; Mathijssen RH; de Jonge MJ
    Clin Cancer Res; 2014 Sep; 20(18):4776-83. PubMed ID: 25024258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
    Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
    Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.
    Sun Y; Yang L; Hao X; Liu Y; Zhang J; Ning Z; Shi Y
    J Hematol Oncol; 2019 Jan; 12(1):9. PubMed ID: 30642372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
    de Weger VA; Goel S; von Moos R; Schellens JHM; Mach N; Tan E; Anand S; Scott JW; Lassen U
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):73-80. PubMed ID: 29101463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
    Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
    Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
    Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
    Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.
    Do K; Wilsker D; Ji J; Zlott J; Freshwater T; Kinders RJ; Collins J; Chen AP; Doroshow JH; Kummar S
    J Clin Oncol; 2015 Oct; 33(30):3409-15. PubMed ID: 25964244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.
    Konings IR; de Jonge MJ; Burger H; van der Gaast A; van Beijsterveldt LE; Winkler H; Verweij J; Yuan Z; Hellemans P; Eskens FA
    Br J Cancer; 2010 Sep; 103(7):987-92. PubMed ID: 20823884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.
    Baselga J; Mita AC; Schöffski P; Dumez H; Rojo F; Tabernero J; DiLea C; Mietlowski W; Low C; Huang J; Dugan M; Parker K; Walk E; van Oosterom A; Martinelli E; Takimoto CH
    Clin Cancer Res; 2012 Nov; 18(22):6364-72. PubMed ID: 23014528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
    Dickson MA; Gordon MS; Edelman G; Bendell JC; Kudchadkar RR; LoRusso PM; Johnston SH; Clary DO; Schwartz GK
    Invest New Drugs; 2015 Apr; 33(2):349-56. PubMed ID: 25476894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
    Kim TM; Lee KW; Oh DY; Lee JS; Im SA; Kim DW; Han SW; Kim YJ; Kim TY; Kim JH; Han H; Kim WH; Bang YJ
    Cancer Res Treat; 2018 Jul; 50(3):835-842. PubMed ID: 28859471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.